Drugs / PU-AD
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04311515 Comparator | Jun → Sep 2020 | Alzheimer disease | Samus Therapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PU-AD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04311515 ↗ |
| Route | Oral | “During the 24 Week Treatment Period, subjects will be administered 30 mg PU AD or matching 30 mg placebo qd, orally.” NCT04311515 ↗ |